-
Strong Outlook, Pullback On Shares Lead Janney To Upgrade RGC Resources
Tuesday, February 6, 2018 - 2:41pm | 440Read More...RGC Resources Inc. (NASDAQ: RGCO) reported fiscal 2018 first-quarter results Monday that were hurt by charges tied to U.S. tax legislation. The Analyst Janney analyst Michael Gaugler upgraded RGC Resources from Neutral to Buy and lowered the fair value estimate from $29 to $27. The...
-
First Solar's Outlook Dims After Q3 Results
Thursday, November 3, 2016 - 10:07am | 279Read More...Janney downgraded First Solar, Inc. (NASDAQ: FSLR) to Neutral from Buy on tepid outlook and lower module prices that sets tone for a difficult earnings for 2017 and 2018. Driven by tax benefits, First Solar’s third quarter non-GAAP EPS of $1.22 was well above Janney’s $0.78 forecast...
-
Agree Realty Gets The Nod Of Approval From Janney
Monday, October 17, 2016 - 10:58am | 303Read More...Janney maintained its Buy rating and $53 fair value estimate on Agree Realty Corporation (NYSE: ADC) as it expects the company to maintain its strong growth profile. “We continue to expect above average earnings and dividend growth over the next few years, and combined with an attractive...
-
CONE Midstream Initiated At Buy From Janney On Attractive Valuation
Thursday, September 1, 2016 - 12:24pm | 401Read More...Janney has started coverage of CONE Midstream Partners LP (NYSE: CNNX) with a Buy rating, saying the company offers investors exposure to a "top tier natural gas shale formation at a reasonable valuation." The brokerage sees volumes in the core Marcellus growing post 2017 to meet U.S. natural gas...
-
Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At $64
Tuesday, August 30, 2016 - 12:16pm | 552Read More...Janney has initiated coverage of Galapagos NV (ADR) (NASDAQ: GLPG) with a Buy rating and fair value estimate of $64, citing potential success of Filgotinib. Galapagos has deals with Gilead Sciences, Inc. (NASDAQ: GILD) and AbbVie Inc (NYSE: ABBV) for the development of Filgotinib in inflammatory...
-
Janney Initiates Jazz Pharma At Neutral, Cites Potential Competition For 'Blockbuster Narcolepsy Franchise'
Thursday, August 25, 2016 - 3:52pm | 367Read More...Janney started coverage of Jazz Pharmaceuticals plc - Ordinary Shares (NASDAQ: JAZZ) with a Neutral rating, citing potential competition to its blockbuster narcolepsy franchise. Jazz's history was based on the growth of narcolepsy drug Xyrem, but its future is dependent upon the success of...
-
Downside Risk In Sarepta Shares Greater Than Upside Potential, Janney Says
Wednesday, August 10, 2016 - 10:32am | 376Read More...A Wall Street Journal opinion piece suggested some eteplirsen reviewers might have escalated the conflict within the agency through a “differing-professional-opinions” (DPO) proceeding. Janney’s Debjit Chattopadhyay maintained a Neutral rating on Sarepta Therapeutics Inc (...
-
Sum-Of-The-Parts Analysis On Chesapeake Utilities Leads Janney To Upgrade Stock
Monday, August 8, 2016 - 4:55pm | 287Read More...Janney upgraded Chesapeake Utilities Corporation (NYSE: CPK) to Buy from Neutral, lifting its price target to $71 from $59. In the report published Monday, the analysts noted that the company's 2Q16 results showed solid improvement YoY and came in well above the consensus forecast. They believe...
-
First Solar Bulls Get Burned Following Q2 Beat
Thursday, August 4, 2016 - 2:16pm | 366Read More...First Solar, Inc. (NASDAQ: FSLR) bulls are enduring a frustrating trading session on Thursday. The stock is down 11.3 percent on the day following Q2 earnings and revenue beats. First Solar charged $86 million in Q2 when it decided to no longer make solar panels using TetraSun’s silicon...
-
Janney Analyst Raises Genesis Energy's Fair Value Estimate, Cites Increased Execution Confidence
Thursday, June 16, 2016 - 9:20am | 340Read More...Janney analyst Akil Marsh raised the fair value of Genesis Energy, L.P. (NYSE: GEL) unit to $44 from $32 on higher execution confidence. The brokerage kept a rating of Buy on the shares of the company. The analyst stated Janney has "increased confidence" that Genesis Energy "will execute on its de...
-
CareDx Reported Positive Clinical Results For Its Kidney Transplant Blood Tests
Wednesday, June 15, 2016 - 5:47pm | 130Read More...CareDx, Inc. (NASDAQ: CDNA) revealed promising clinical performance of its AlloSure assay for the non-invasive surveillance of kidney transplant rejection, according to a note from analysts at Janney. In patients studied as part of a DART clinical trial, CareDx’s “AlloSure”...
-
Cynapsus Therapeutics Developing New Parkinson's Treatment That Won't Require Injection
Wednesday, June 15, 2016 - 4:07pm | 186Read More...Janney's Ken Trbovich initiated a Buy rating on Cynapsus Therapeutics Inc (Nasdaq: CYNA) and set a price target of $24. The company has successfully developed and marketed Apomorphine (APO) for 20 years to combat Parkinson's disease in Europe and the US. A relatively big drawback for...
-
Janney Upgrades Equity Residential
Wednesday, May 18, 2016 - 1:25pm | 276Read More...Equity Residential (NYSE: EQR) reduced its same-store and earnings guidance for 2016. Janney’s Robert Stevenson upgraded the rating for the company to Buy, with a fair value of $78. The analyst commented that shares were trading at an attractive valuation versus apartment peers. Negative...
-
Janney: Time To Buy Boyd Gaming Ahead Of Las Vegas And Atlantic City Strength
Tuesday, March 22, 2016 - 9:15am | 220Read More...Janney’s Brian McGill upgraded the rating for Boyd Gaming Corporation (NYSE: BOYD) from Neutral to Buy, while raising the fair value from $21 to $25. The analyst believes that the company is poised to benefit from strong gaming growth trends in its regional business, the Las Vegas locals...
-
Janney Upgrades Amicus, Says EU Approval 'Likely'
Tuesday, March 8, 2016 - 10:09am | 257Read More...Janney’s Roy Buchanan upgraded the rating for Amicus Therapeutics, Inc. (NASDAQ: FOLD) from Neutral to Buy, while raising the fair value estimate from $10 to $12. He said that although there was uncertainty regarding the FDA’s decision on migalastat in Fabry’s, a CHMP opinion...
